Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 6.4%

Stoke Therapeutics (NASDAQ:STOK)’s share price rose 6.4% during mid-day trading on Tuesday . The company traded as high as $30.47 and last traded at $30.00, approximately 287,797 shares were traded during trading. An increase of 70% from the average daily volume of 169,031 shares. The stock had previously closed at $28.19.

STOK has been the subject of a number of recent analyst reports. Canaccord Genuity initiated coverage on Stoke Therapeutics in a research report on Monday, July 15th. They set a “buy” rating and a $44.00 target price for the company. JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics in a research report on Monday, July 15th. They set an “overweight” rating and a $34.00 target price for the company. Credit Suisse Group initiated coverage on Stoke Therapeutics in a report on Monday, July 15th. They set an “outperform” rating and a $35.00 price target for the company. Finally, Cowen initiated coverage on Stoke Therapeutics in a report on Monday, July 15th. They set an “outperform” rating for the company.

The firm has a fifty day moving average of $26.36.



In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp purchased 555,556 shares of the business’s stock in a transaction dated Wednesday, June 19th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $10,000,008.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Apple Tree Partners Iv, L.P. purchased 1,388,889 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were acquired at an average price of $18.00 per share, with a total value of $25,000,002.00. The disclosure for this purchase can be found here.

Several hedge funds have recently modified their holdings of STOK. Janus Henderson Group PLC acquired a new position in shares of Stoke Therapeutics during the second quarter valued at $11,668,000. Monashee Investment Management LLC acquired a new position in shares of Stoke Therapeutics during the second quarter valued at $2,177,000. BlackRock Inc. acquired a new position in shares of Stoke Therapeutics during the second quarter valued at $1,332,000. Finally, Laurion Capital Management LP acquired a new position in shares of Stoke Therapeutics during the second quarter valued at $729,000. Institutional investors own 1.42% of the company’s stock.

About Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Featured Story: The mechanics of the bid-ask spread in trading

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.